UNC Health

     System Formulary Restriction:

     Inpatient use of asparaginase erwinia chrysanthemi (recombinant)-rywn (Rylaze) is restricted to patients who meet all of the following:

• Patients ≥ 1 month of age with acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL) 
• Documented hypersensitivity reactions to pegylated asparaginase products
• Orders must be signed by a Hematology/Oncology Physician

     Use for all other indications is restricted to outpatient encounters or clinic use only (ie, no inpatient use)

• Lexicomp
• Micromedex
• UpToDate
• FDA Daily Med